MX2022005250A - Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. - Google Patents
Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.Info
- Publication number
- MX2022005250A MX2022005250A MX2022005250A MX2022005250A MX2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A
- Authority
- MX
- Mexico
- Prior art keywords
- capivasertib
- acalabrutinib
- treat
- therapeutic combinations
- cell malignancies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación se refiere, en general, a combinaciones terapéuticas de acalabrutinib y capivasertib, y a los correspondientes métodos de tratamiento, composiciones farmacéuticas y kits.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962930208P | 2019-11-04 | 2019-11-04 | |
PCT/EP2020/080493 WO2021089419A1 (en) | 2019-11-04 | 2020-10-30 | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005250A true MX2022005250A (es) | 2022-06-08 |
Family
ID=73043259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005250A MX2022005250A (es) | 2019-11-04 | 2020-10-30 | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220401442A1 (es) |
EP (1) | EP4054582A1 (es) |
JP (1) | JP2023501317A (es) |
KR (1) | KR20220098175A (es) |
CN (1) | CN114728003A (es) |
AU (1) | AU2020381240C1 (es) |
CA (1) | CA3158321A1 (es) |
MX (1) | MX2022005250A (es) |
WO (1) | WO2021089419A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
WO2024104561A1 (en) * | 2022-11-15 | 2024-05-23 | Astrazeneca Ab | Therapeutic combinations of capivasertib and venetoclax |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
MY192354A (en) | 2011-07-19 | 2022-08-17 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
US20170071962A1 (en) * | 2015-09-11 | 2017-03-16 | Acerta Pharma B.V. | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor |
US10316049B2 (en) * | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
CN107344940B (zh) * | 2016-05-06 | 2020-04-21 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
-
2020
- 2020-10-30 MX MX2022005250A patent/MX2022005250A/es unknown
- 2020-10-30 JP JP2022525916A patent/JP2023501317A/ja active Pending
- 2020-10-30 AU AU2020381240A patent/AU2020381240C1/en active Active
- 2020-10-30 EP EP20800617.1A patent/EP4054582A1/en active Pending
- 2020-10-30 US US17/755,548 patent/US20220401442A1/en active Pending
- 2020-10-30 CN CN202080076132.6A patent/CN114728003A/zh active Pending
- 2020-10-30 WO PCT/EP2020/080493 patent/WO2021089419A1/en unknown
- 2020-10-30 KR KR1020227018891A patent/KR20220098175A/ko active Search and Examination
- 2020-10-30 CA CA3158321A patent/CA3158321A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020381240A1 (en) | 2022-06-23 |
AU2020381240B2 (en) | 2023-09-07 |
KR20220098175A (ko) | 2022-07-11 |
JP2023501317A (ja) | 2023-01-18 |
US20220401442A1 (en) | 2022-12-22 |
CN114728003A (zh) | 2022-07-08 |
EP4054582A1 (en) | 2022-09-14 |
WO2021089419A1 (en) | 2021-05-14 |
CA3158321A1 (en) | 2021-05-14 |
AU2020381240C1 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
MY179105A (en) | Methods of treating alzheimer's disease | |
MX2018009173A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
EA201890968A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
MX2020001727A (es) | Terapia de combinacion. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
MX2019013862A (es) | Terapia de combinacion. | |
PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
MX2022005250A (es) | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. | |
MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. |